<DOC>
	<DOCNO>NCT00784758</DOCNO>
	<brief_summary>The purpose study investigate effect Fenzian™ treatment symptom ( shortness breath ) , lung function ( well lung work ) , albuterol/salbutamol ( rescue medication ) use people asthma . This do comparing effect Fenzian™ treatment effect sham treatment , look Fenzian™ device n't anything . The Fenzian™ device electrical instrument investigator hope help reduce airway inflammation associate asthma symptom stimulate nerve low electrical current . The study device apply directly skin back , work along ribs toward spine , alternate leave right side , face .</brief_summary>
	<brief_title>Fenzian Asthma Multicenter Outcomes Study</brief_title>
	<detailed_description>Note regard blind study : subject , investigator , assessor blind treatment arm ( Fenzian sham ) subject assign . However , treatment coordinator , administers Fenzian ( sham ) treatment , unblinded . Therefore , design study neatly fit either `` single blind '' `` double blind '' category . We would call study design `` subject observer blind '' one involve assessment study outcomes unblinded . Unfortunately , clinicaltrials.gov system post allow u indicate `` single blind '' AND check multiple masked role . For reason , explanation accompany discussion blinding ; subject , investigator , assessor blind ( check ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Ages 1280 year . [ NOTE : Only Johns Hopkins site enroll subject 18 . ] Clinical history consistent asthma ( GINA 4 definition ) least six month Current symptom feature partlycontrolled uncontrolled asthma , accord GINA classification asthma control A stable ( 1 month ) treatment regimen consist : need shortacting bronchodilator alone , need shortacting bronchodilator combination low mediumdose inhaled corticosteroid ( &lt; = 1000 mcg per day beclomethasone equivalent , combination long act betaagonist bronchodilator low mediumdose inhale corticosteroid ( define ) , need shortacting bronchodilator combination montelukast leukotriene modifier Willingness comply study protocol ability perform study procedure . Willingness attend study site accord specify treatment schedule Inclusion Criteria Assessed Visit 1 : Prebronchodilator FEV1 60 % predict low limit normal . Prebronchodilator FEV1/FVC less low limit normal . Reversibility FEV1 least 200 ml , 1520 minute 4 puff albuterol HFA pressurize metereddose inhaler pMDI . Inclusion Criteria Assessed Visit 2 : Reversibility FEV1 least 200ml , 1530 minute 4 puff albuterol HFA pMDI confirm Visit 1 plus Using shortacting bronchodilator therapy two occasion two week precede Visit 2 plus ( Ventolin HFA counter decrease least 8 puff ) Partly control uncontrolled asthma indicate one three , four follow two week precede Visit 2 : Daytime symptom twice per week Any limitation activity Any nocturnal symptom awaken PEF &lt; 80 % predict day Pulmonary disease asthma , smokingrelated COPD , clinically significant bronchiectasis , lung resection , interstitial lung disease . Other significant systemic illness might , opinion investigator alter risk outcome study ( e.g . cardiovascular arrhythmias conduction abnormality , hyperthyroidism , uncontrolled hypertension , cancer ) Tobacco smoke great 10 packyear cumulative exposure current smoking within 10 year . Respiratory tract infection within 6 week study . Seasonal allergy cause symptom within past 4 week . Perennial season allergic rhinitis acceptable . Nasal corticosteroids longacting antihistamine acceptable . Any investigational drug treatment within 30 day . Use cromolyn , nedocromil , theophylline , tiotropium , oral albuterol within 1 week prior Visit 1 study . Current use omalizumab within last 8 week . Subjects antidepressant ( monoamine oxidase inhibitor tricyclic antidepressant ) treatment within 8 week . Nonpotassium spar diuretic unless fix combination potassium spar diuretic within one week . Digoxin , within one week , unless level monitor previously take albuterol LABAs . Presence implant cardiac pacemaker neurostimulator . A removable transcutaneous nerve stimulator , use treatment session acceptable . Nonselective beta agonist . ( acceptable choice include : bisproprolol , betaxolol , atenolol , acebutolol metoprolol ) Subjects pregnant breast feeding . Persons employ related employed investigative site ( e.g . Pulmonary Division ) . Prior Fenzian treatment indication Hypersensitivity intolerance albuterol HFA pMDI ( Ventolin ) component . Note : subject use ipratropium bromide rescue shortacting bronchodilator , must specifically place treatment due intolerance albuterol/salbutamol . Inability withhold , visit ( except initial consent visit ) , xanthinecontaining food ( coffee , tea , cola , chocolate , etc . ) alcohol 6 hour , shortacting bronchodilator 8 hour . Unwillingness stop use nonstudy supply albuterol ( nebulized , CFC HFA ) , shortacting beta agonist ( e.g . epinephrine , levalbuterol , metaproterenol , pirbuterol , terbutaline ) ipratropium study ( consent visit 4 ) . Inability coordinate timing dose longacting beta agonist ( withhold period least 12 hour prior visit ) Visits 1 , 2 , 3 4</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Lung Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
</DOC>